Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2023-04-26 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 截止2023年3月31日前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by 百奥泰生物制药股份有限公司 as of March 31, 2023. It includes specifics on the amount raised, usage, balance, investment projects, changes in fund usage, and cash management of idle funds. The document references regulatory approvals and audit verification by an accounting firm. The content focuses on the management and use of capital raised from a prior fundraising event, consistent with a capital/financing update. It is not an annual or interim financial report, nor an earnings release or management discussion. The document is substantive and over 5,000 characters, containing detailed financial data about fundraising and fund usage, which fits the Capital/Financing Update category (CAP).
2023-04-26 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司部分募投项目子项目变更及金额调整的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from China International Capital Corporation Limited regarding changes and adjustments in sub-projects and amounts of fundraising investment projects for Bio-Thera Solutions Ltd. It references regulatory approvals, fundraising amounts, and detailed use of funds for various drug development projects. The document includes audit opinions, board and supervisory committee approvals, and independent director opinions. It is not a simple announcement but a comprehensive verification and opinion report on fundraising project changes, including financial figures and regulatory compliance. This fits the category of an Audit Report / Information (AR) as it involves audit verification and regulatory compliance related to fundraising projects, rather than a full annual report or a simple announcement. The document length (8065 characters) and content depth support this classification.
2023-04-26 Chinese
百奥泰 关于公司2023年度董事、监事和高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2023 annual remuneration scheme for the company's directors, supervisors, and senior management. It details the salary arrangements and independent directors' opinions on the remuneration plan. It references compliance with company law and governance standards but does not contain financial statements or detailed financial performance data. The document is a formal announcement of management remuneration information rather than a full remuneration report or proxy statement. Therefore, it fits best under the Remuneration Information category (DEF 14A). The document length and content confirm it is not a full annual report or other financial filing.
2023-04-26 Chinese
百奥泰 关于使用部分暂时闲置募集资金进行现金管理及追认使用部分暂时闲置募集资金进行现金管理的公告-
Capital/Financing Update Classification · 95% confidence The document is an announcement by 百奥泰生物制药股份有限公司 regarding the use of temporarily idle raised funds for cash management and the ratification of such use. It details the board meeting resolutions, investment products, amounts, risk controls, and regulatory compliance related to the use of idle raised funds. The document references regulatory guidelines on raised funds management and includes independent director opinions and sponsor institution verification. It does not contain financial statements or detailed financial results but is a formal disclosure about the company's capital management activities related to raised funds. This fits the definition of a Capital/Financing Update (CAP) as it updates on the company's use of capital raised through fundraising and its management thereof. The document length is over 7,000 characters and contains substantive content about capital use, not merely an announcement of a report publication or a certification. Therefore, the appropriate classification is CAP with high confidence.
2023-04-26 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司2022年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导工作现场检查报告" (2022 Annual Continuous Supervision On-site Inspection Report) by China International Capital Corporation Limited regarding Bai'ao Tai Biopharmaceutical Co., Ltd. It is addressed to the Shanghai Stock Exchange and references regulatory approvals and supervision activities related to the company's IPO and ongoing compliance. The content details the scope and findings of the on-site inspection, including governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, and operational status. It also discusses regulatory letters received and the company's corrective actions. The document is a detailed audit and supervisory report by the sponsor institution, focusing on compliance and internal controls rather than a full annual report or financial statements. It is not an announcement or a brief summary but a substantive report on regulatory supervision and audit findings. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/supervisory report with detailed findings and regulatory compliance information, excluding a full annual report. The document length (4335 characters) is sufficient for a detailed report but not a full annual report. Therefore, the classification is AR with high confidence.
2023-04-26 Chinese
百奥泰 2022年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, their identification, and rectification. The document includes detailed internal control standards, evaluation scope, and conclusions about the effectiveness of internal controls. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The content aligns with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluation results. The document is 4542 characters long, which is sufficient to be a full report rather than a brief announcement. Therefore, the appropriate classification is AR with high confidence.
2023-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.